Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1970 1
1971 2
1972 1
1974 2
1975 1
1977 2
1979 2
1980 1
1981 2
1982 3
1983 1
1984 4
1985 1
1986 4
1987 1
1988 4
1989 3
1990 6
1991 5
1992 6
1993 8
1994 8
1995 7
1996 9
1997 8
1998 19
1999 23
2000 24
2001 23
2002 23
2003 27
2004 29
2005 53
2006 49
2007 54
2008 54
2009 70
2010 101
2011 71
2012 96
2013 80
2014 94
2015 117
2016 108
2017 107
2018 108
2019 62
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,348 results
Results by year
Filters applied: . Clear all
Page 1
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Valle J, et al. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721. N Engl J Med. 2010. PMID: 20375404 Free article. Clinical Trial.
New Horizons for Precision Medicine in Biliary Tract Cancers.
Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. Valle JW, et al. Cancer Discov. 2017 Sep;7(9):943-962. doi: 10.1158/2159-8290.CD-17-0245. Epub 2017 Aug 17. Cancer Discov. 2017. PMID: 28818953 Free PMC article. Review.
Targeted Therapy in Biliary Tract Cancers.
Merla A, Liu KG, Rajdev L. Merla A, et al. Curr Treat Options Oncol. 2015 Oct;16(10):48. doi: 10.1007/s11864-015-0366-0. Curr Treat Options Oncol. 2015. PMID: 26266637 Free PMC article. Review.
Gallbladder Cancer.
Baiu I, Visser B. Baiu I, et al. JAMA. 2018 Sep 25;320(12):1294. doi: 10.1001/jama.2018.11815. JAMA. 2018. PMID: 30264121 No abstract available.
Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P, Marino D, Fenocchio E, ChilĂ  G, Aglietta M, Leone F. Lombardi P, et al. Expert Opin Emerg Drugs. 2018 Mar;23(1):63-75. doi: 10.1080/14728214.2018.1444749. Epub 2018 Feb 28. Expert Opin Emerg Drugs. 2018. PMID: 29468924 Free article. Review.
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Mizusawa J, Morizane C, Okusaka T, Katayama H, Ishii H, Fukuda H, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. Mizusawa J, et al. Jpn J Clin Oncol. 2016 Apr;46(4):385-8. doi: 10.1093/jjco/hyv213. Epub 2016 Feb 18. Jpn J Clin Oncol. 2016. PMID: 27025903 Free PMC article. Clinical Trial.
Emerging molecular therapeutic targets for cholangiocarcinoma.
Rizvi S, Gores GJ. Rizvi S, et al. J Hepatol. 2017 Sep;67(3):632-644. doi: 10.1016/j.jhep.2017.03.026. Epub 2017 Apr 5. J Hepatol. 2017. PMID: 28389139 Free PMC article. Review.
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Marubashi S, Miyamoto A, Shiomi H, Kubo S, Ikuta S, Yanagimoto H, Terajima H, Ikoma H, Sakai D, Kodama Y, Seo S, Morita S, Ajiki T, Nagano H, Ioka T. Kanai M, et al. Cancer Chemother Pharmacol. 2015 Feb;75(2):293-300. doi: 10.1007/s00280-014-2648-9. Epub 2014 Dec 5. Cancer Chemother Pharmacol. 2015. PMID: 25477010 Free article. Clinical Trial.
1,348 results
Jump to page
Feedback